北海康成製藥有限公司(“北海康成-B”)于2026年7月2日发布截至2026年5月31日的股份变动月报表。报告期内，公司法定/注册股本维持在5,000,000,000股，面值每股0.00001美元，法定/注册股本总额为50,000美元，无增减变化。
报告显示，公司已发行股份（不含库存股份）自上月底的595,443,347股增加至597,443,347股，增幅为2,000,000股。本月无股份购回或注销活动。期权与激励计划方面，首次公开发售后购股权计划本月内有30,000股期权失效，剩余可发或转让的股份指标为4,311,025股；首次公开发售后受限制股份单位计划于本月新增发行2,000,000股股份。此外，首发前股权激励计划保留了20,695,760股的潜在发行额度。截至本月末，公司确认其已符合适用的公众持股量要求。
据公告披露，本次月报由公司董事长薛群博士签署。公司表示，将继续严格遵守香港联交所《上市规则》及相关法律法规。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.